News

Damage to certain nerve fibers in the extremities, known as peripheral neuropathy, was evident in some people with Parkinson’s disease, including those at early disease stages, a study reported. Findings in this work, which used a sensitive electrophysiological device to examine nerves, also suggested that peripheral neuropathy was related…

WCG IRB will now serve as the institutional review board (IRB) for the Michael J. Fox Foundation’s (MJFF) ongoing Parkinson’s Progression Markers Initiative (PPMI) study, WCG announced. The PPMI study (NCT04477785), renamed PPMI 2.0 in July 2020, is a longitudinal, observational study of individuals with and without…

PreciseDx’s artificial intelligence (AI) platform shows an ability to accurately diagnose Parkinson’s disease in people before they develop severely evident symptoms, according to a new study. Conducted in collaboration with The Michael J. Fox Foundation (MJFF), the study’s findings support the platform’s potential to aid in diagnosing Parkinson’s and allowing patients to begin…

A research team in Canada is embarking on a project that will apply MRI to identify new biomarkers for diagnosing Parkinson’s disease and monitoring its progression over time. The potential findings may speed Parkinson’s diagnoses and help patients receive treatment sooner. Identifying easily recognizable MRI signatures of Parkinson’s could…

The Riverside Health & Rehabilitation Center, an affiliate of National Health Care Associates, now has a comprehensive program aimed at improving physical health and cognition for those with Parkinson’s disease. The program, housed at Riverside’s facility in East Hartford, Connecticut, is also open for people…

A three-month community-based boxing program significantly eased motor and non-motor symptoms, as well as depression, in adults with early Parkinson’s disease, a pilot study showed. These preliminary findings support larger and longer studies into the benefits of such programs, which also could include people with more advanced disease. Results were…

Enrollment is complete in the Phase 2 study evaluating Neuraly‘s NLY01, an investigational disease-modifying agent designed to slow or stop Parkinson’s disease progression by protecting nerve cells and limiting neuroinflammation. Top-line results from the trial, which enrolled 255 people with early Parkinson’s at 60 sites in the U.S. and Canada,…

To help mark Parkinson’s Awareness Month, members of the Michael J. Fox Foundation’s (MJFF) public policy team persuaded 17 local governments to issue proclamations and resolutions recognizing the annual event that brings Parkinson’s disease to greater attention. Team members engaged legislators in their local areas, arguing in favor of the city,…

PolyCore Therapeutics has secured a seed investment to advance its lead compound PCT-3012, designed to treat motor symptoms in Parkinson’s disease without triggering levodopa-induced dyskinesia, or uncontrollable body movements. The investment, by Xontogeny and Ben Franklin Technology Partners, will enable studies supporting a potential…

Telehealth services during the COVID-19 pandemic was perceived to be a good alternative to in-person healthcare appointments among people with Parkinson’s disease, according to an anonymous survey. Respondents said telehealth reduced travel, was more convenient, was suitable for follow-up appointments, and was preferred for speech-language pathology and mental health…